We are committed to the safety of our medicines in all cases, and maintain an active pharmacovigilance programme to help ensure this.

Through our robust commitment to pharmacovigilance, we ensure we remain focused on patients' safety. Our Pharmacovigilance Department manages a pharmacovigilance system for the collection, collation, and evaluation of adverse events and the implementation of effective corrective and preventive actions.

For medical information enquiries, complaints and adverse events reporting, contact: pv@hikma.com

or

Canada: Canada_DrugSafety@hikma.com 

France: francepv@hikma.com

Germany: dl-muc-qs@hikma.com

Italy: portugaleupharmacovigilance@hikma.com or call +351 939 610 004

Portugal:portugaleupharmacovigilance@hikma.com or call +351 939 610 004

The Netherlands: beneluxqapv@hikma.com

US: us.hikma@primevigilance.com or call +1-877-845-0689 or 1-800-962-8364, or you can contact the FDA directly at 1-800-FDA-1088 or www.fda.gov/medwatch